Metachromatic leukodystrophy is a lysosomal storage disorder caused by
the deficiency of arylsulphatase A. The disease is characterized by a
progressive demyelination that causes a variety of neurological sympt
oms. Patients die within a few years after the age of onset. Clinicall
y the disease is heterogeneous and according to the age of onset three
different forms can be distinguished. The gene of arylsulphatase A ha
s been cloned and several mutations causing metachromatic leukodystrop
hy have been characterized. The distribution of these alleles among pa
tients with different clinical forms of the disease has revealed a gen
otype-phenotype correlation. A major determinant of the clinical pheno
type is the residual enzyme activity that it associated with a particu
lar genotype. Homozygosity for alleles that do not allow the synthesis
of arylsulphatase A polypeptides causes the most severe form of disea
se, whereas homozygosity for alleles that encode arylsulphatase A with
low residual enzyme activity is found in the mild late-onset forms of
disease. A substantial arylsulphatase A deficiency can also be found
in healthy individuals at high frequency. This phenomenon has been ter
med pseudodeficiency. It is often difficult to distinguish whether an
arylsulphatase A deficiency is due to metachromatic leukodystrophy or
harmless pseudodeficiency. The characterization of the mutations causi
ng pseudodeficiency has allowed the detection of the pseudodeficiency
allele in the DNA of probands and has thus improved the diagnosis and
genetic counselling for metachromatic leukodystrophy.